Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 7Withdrawn 1Unknown 1Suspended 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 6384Neoplasms 5356Prostatic Neoplasms 2964Carcinoma, Non-Small-Cell Lung 2704Colorectal Neoplasms 2674Lung Neoplasms 2262Multiple Myeloma 1656Lymphoma 1598Neoplasm Metastasis 1550Leukemia, Myeloid, Acute 1537Melanoma 1484Pancreatic Neoplasms 1470Ovarian Neoplasms 1420Leukemia 1387Head and Neck Neoplasms 1283Precursor Cell Lymphoblastic Leukemia-Lymphoma 1279Lymphoma, Non-Hodgkin 1226Colonic Neoplasms 1157Carcinoma, Hepatocellular 1141Stomach Neoplasms 1126Leukemia, Lymphocytic, Chronic, B-Cell 1089Brain Neoplasms 1048Rectal Neoplasms 979Lymphoma, Follicular 978Recurrence 971Uterine Cervical Neoplasms 923Glioblastoma 916Carcinoma, Renal Cell 881Lymphoma, Large B-Cell, Diffuse 851Hodgkin Disease 775

Interventions

midostaurin 1Nivolumab 1Injections 1Decitabine 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × GATA2 Deficiency × Clear all
NCT03092674 2025-01-16

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2/3 Completed
76 enrolled 16 charts
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡